CAMBRIDGE, Mass. (AP) _ Seres Therapeutics Inc. (MCRB) on Tuesday reported a loss of $35.5 million in its first quarter.

On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 39 cents.

The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 33 cents per share.

The drug developer posted revenue of $5.7 million in the period, exceeding Street forecasts. Three analysts surveyed by Zacks expected $5.3 million.

Seres Therapeutics shares have declined 17% since the beginning of the year. The stock has climbed fivefold in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MCRB at https://www.zacks.com/ap/MCRB